Tandem Diabetes Care [TNDM] vs Abbott Laboratories [ABT] Detailed Stock Comparison

Tandem Diabetes Care Inc.

NASDAQ
Loading...

Abbott Laboratories

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Tandem Diabetes Care Inc. wins in 4 metrics, Abbott Laboratories wins in 15 metrics, with 0 ties. Abbott Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Tandem Diabetes Care Inc. Abbott Laboratories Better
P/E Ratio (TTM) -6.80 25.97 Abbott Laboratories
Price-to-Book Ratio 8.82 3.09 Abbott Laboratories
Debt-to-Equity Ratio 289.60 26.79 Abbott Laboratories
PEG Ratio 0.03 -1.41 Tandem Diabetes Care Inc.
EV/EBITDA -25.23 13.74 Abbott Laboratories
Profit Margin (TTM) -20.17% 13.90% Abbott Laboratories
Operating Margin (TTM) 2.86% 16.50% Abbott Laboratories
EBITDA Margin (TTM) 2.86% 16.50% Abbott Laboratories
Return on Equity -97.89% 12.36% Abbott Laboratories
Return on Assets (TTM) -5.28% 7.52% Abbott Laboratories
Free Cash Flow (TTM) $-108.26M $7.40B Abbott Laboratories
Dividend Yield N/A 1.97% N/A
1-Year Return -20.04% -34.98% Tandem Diabetes Care Inc.
Price-to-Sales Ratio (TTM) 1.35 3.57 Tandem Diabetes Care Inc.
Enterprise Value $1.53B $166.96B Abbott Laboratories
EV/Revenue Ratio 1.50 3.70 Tandem Diabetes Care Inc.
Gross Profit Margin (TTM) 57.67% N/A N/A
Revenue per Share (TTM) $15 $26 Abbott Laboratories
Earnings per Share (Diluted) $-3.04 $3.57 Abbott Laboratories
Beta (Stock Volatility) 1.74 0.78 Abbott Laboratories
Short % of Float 20.70% 1.53% Abbott Laboratories

Tandem Diabetes Care Inc. vs Abbott Laboratories Stock Performance Analysis

Loading Price Chart...

TNDM
ABT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Tandem Diabetes Care Inc.0.96%-9.26%30.73%-23.51%-24.20%-22.23%
Abbott Laboratories0.56%-2.02%4.97%-19.35%-30.98%-28.60%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Tandem Diabetes Care Inc.-20.04%-38.75%-82.30%-77.45%-92.40%-92.40%
Abbott Laboratories-34.98%-16.97%-20.08%135.84%255.56%329.52%

Performance & Financial Health Analysis: Tandem Diabetes Care Inc. vs Abbott Laboratories

MetricTNDMABT
Market Information
Market Cap i$1.42B$160.70B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i1,506,21113,495,583
90 Day Avg. Volume i1,785,89412,934,461
Last Close$16.76$88.67
52 Week Range$9.98 - $29.65$81.97 - $139.06
% from 52W High-43.47%-36.24%
All-Time High$302.50 (Jan 13, 2014)$142.60 (Dec 27, 2021)
% from All-Time High-94.46%-37.82%
Growth Metrics
Quarterly Revenue Growth0.03%0.08%
Quarterly Earnings GrowthN/A-0.19%
Financial Health
Profit Margin (TTM) i-0.20%0.14%
Operating Margin (TTM) i0.03%0.17%
Return on Equity (TTM) i-0.98%0.12%
Debt to Equity (MRQ) i289.6026.79
Cash & Liquidity
Book Value per Share (MRQ)$2.27$30.02
Cash per Share (MRQ)$4.28$5.14
Operating Cash Flow (TTM) i$-9,721,000$10.80B
Levered Free Cash Flow (TTM) i$-44,731,124$13.77B
Dividends
Last 12-Month Dividend Yield iN/A1.97%
Last 12-Month Dividend iN/A$2.40

Valuation & Enterprise Metrics Analysis: Tandem Diabetes Care Inc. vs Abbott Laboratories

MetricTNDM (Apr 24, 2026)ABT (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-6.8025.97
Forward P/E i-848.0115.29
PEG Ratio i0.03-1.41
Price to Sales (TTM) i1.353.57
Price to Book (MRQ) i8.823.09
Market Capitalization
Market Capitalization i$1.42B$160.70B
Enterprise Value i$1.53B$166.96B
Enterprise Value Metrics
Enterprise to Revenue i1.503.70
Enterprise to EBITDA i-25.2313.74
Risk & Other Metrics
Beta i1.740.78
Book Value per Share (MRQ) i$2.27$30.02

Financial Statements Comparison: Tandem Diabetes Care Inc. vs Abbott Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricTNDM (2025)ABT (2025)
Revenue/Sales i1.01B44.33B
Cost of Goods Sold i468.72M19.32B
COGS % of Revenue i46.2%43.6%
Gross Profit i546.01M25.01B
Gross Margin i53.8%56.4%
Research & Development i268.33M2.94B
Operating Income (EBIT) i-167.31M8.05B
Operating Margin i-16.5%18.2%
EBITDA i-156.61M12.03B
EBITDA Margin i-15.4%27.1%
Pre-Tax Income i-200.27M8.47B
Pre-Tax Income % of Revenue i-19.7%19.1%
Income Tax i4.44M1.94B
Income Tax % of Revenue i0.4%4.4%
Net Income (Profit) i-204.71M6.52B
Profit Margin i-20.2%14.7%

Balance Sheet & Liquidity Metrics

MetricTNDM (2025)ABT (2025)
Cash & Equivalents i90.63M8.52B
Total Current Assets i618.14M26.00B
Total Current Assets % of Revenue i60.9%58.6%
Total Current Liabilities i242.72M16.50B
Total Current Liabilities % of Revenue i23.9%37.2%
Long-Term Debt i425.00M10.83B
Long-Term Debt % of Revenue i41.9%24.4%
Total Shareholders Equity i155.17M52.77B
Retained Earnings i-1.25B49.78B
Retained Earnings % of Revenue i-123.4%112.3%
Property, Plant & Equipment i99.27M17.57B

Cash Flow Statement Comparison

MetricTNDM (2025)ABT (2025)
Operating Cash Flow i-19.81M10.80B
Operating Cash Flow % of Revenue i-2.0%24.4%
Capital Expenditures i-19.95M-2.17B
Free Cash Flow i-108.26M7.40B
FCF Margin i-10.7%16.7%
Debt Repayment i-40.76M-1.50B
Common Stock Repurchase iN/A-893.00M

Short Interest & Institutional Ownership Analysis

MetricTNDMABT
Shares Short i10.53M23.83M
Short Ratio i5.381.93
Short % of Float i20.70%1.53%
Shares Outstanding i68.29M1.74B
Float Shares i62.60M1.73B
% Held by Insiders i0.75%0.54%
% Held by Institutions i110.78%82.23%
% Held by Public i-11.53%17.23%

Dividend Analysis & Yield Comparison: Tandem Diabetes Care Inc. vs Abbott Laboratories

MetricTNDMABT
Last 12-Month Dividend iN/A$2.40
Last 12-Month Dividend Yield iN/A1.97%
3-Year Avg Annual Dividend iN/A$2.24
3-Year Avg Dividend Yield iN/A0.50%
3-Year Total Dividends iN/A$6.72
Ex-Dividend DateN/AJan 15, 2026